NovaBay Pharmaceuticals Inc (NBY)-医療機器分野:企業M&A・提携分析

◆英語タイトル:NovaBay Pharmaceuticals Inc (NBY) - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA8011484
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月22日
◆ページ数:43
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
NovaBay Pharmaceuticals Inc (NovaBay), formerly NovaCal Pharmaceuticals Inc is a biopharmaceutical company that develops eyecare products. The company’s products include daily lid and lash hygiene spray solution, skin and wound cleanser, and cosetic procedures. Its daily lid and lash hygiene spray solution helps in removal of foreign materials including microorganisms and debris on and around the lid and eyelid margins. NovaBay develops aganocide compound through research and development based on the human body’s natural immune system and molecules involved in combating infections.The company’s products finds application in various therapeutic areas such as wound care, dermatology, ophthalmology, and neutrophase. It partners with pharmaceutical and biotech companies. NovaBay is headquartered in Emeryville, California, the US.

NovaBay Pharmaceuticals Inc (NBY) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
NovaBay Pharmaceuticals Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017 5
NovaBay Pharmaceuticals Inc, Medical Equipment Deals By Type, 2011 to YTD 2017 6
NovaBay Pharmaceuticals Inc, Medical Equipment, Deals By Region, 2011 to YTD 2017 7
NovaBay Pharmaceuticals Inc, Medical Equipment, Deals By Market, 2011 to YTD 2017 8
NovaBay Pharmaceuticals Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 9
NovaBay Pharmaceuticals Inc, Medical Equipment, Deal Details 10
Shin Poong Enters Into Licensing Agreement With NovaBay For NeutroPhase 10
Equity Offering 11
NovaBay Pharma Files Registration Statement for Public Offering of Shares 11
NovaBay Pharma Raises USD4 Million in Second and Final Tranche of Private Placement of Units 12
NovaBay Pharma Raises USD7.8 Million in First Tranche of Private Placement of Units 13
NovaBay Pharma Raises USD2.8 Million in Private Placement of Shares 14
NovaBay Pharma Raises USD6.7 Million in Public Offering of Units 15
NovaBay Pharma Completes Registered Direct Offering Of US$5.16 Million 16
Acquisition 18
Jinzi Ham to Acquire 37.14% Stake in NovaBay Pharma for USD27.06 Million 18
NovaBay Pharmaceuticals Inc – Key Competitors 19
NovaBay Pharmaceuticals Inc – Key Employees 20
NovaBay Pharmaceuticals Inc – Locations And Subsidiaries 21
Head Office 21
Recent Developments 22
Financial Announcements 22
Aug 10, 2017: NovaBay Pharmaceuticals Reports Second Quarter 2017 Financial Results 22
May 11, 2017: NovaBay Pharmaceuticals Reports First Quarter 2017 Financial Results 24
Mar 23, 2017: NovaBay Pharmaceuticals Reports 2016 Full Year and Fourth Quarter Financial Results and Provides 2017 Financial Guidance 26
Jan 09, 2017: Novabay Pharmaceuticals Announces Preliminary Sales For The Fourth Quarter Of 2016 28
Nov 10, 2016: NovaBay Pharmaceuticals Reports 2016 Third Quarter Financial Results 29
Aug 11, 2016: NovaBay Pharmaceuticals Reports 2016 Second Quarter Financial Results 31
May 12, 2016: NovaBay Pharmaceuticals Reports 2016 First Quarter Financial Results 33
Mar 03, 2016: NovaBay Pharmaceuticals Reports 2015 Fourth Quarter and Full Year Financial Results 35
Corporate Communications 37
Jul 10, 2017: NovaBay Pharmaceuticals Announces CFO Transition 37
Jun 13, 2016: NovaBay Pharmaceuticals Appoints Mark M. Sieczkarek President and Chief Executive Officer 38
May 09, 2016: NovaBay Pharmaceuticals Appoints Todd Zavodnick to its Board of Directors 39
Legal and Regulatory 40
Oct 31, 2016: NovaBay Pharmaceuticals Successfully Regains Compliance with NYSE Continued Listing Requirements 40
Product News 41
01/11/2016: NovaBay Pharmaceuticals Expects Fourth Quarter 2015 Avenova Sales to Exceed $1.5 Million 41
Other Significant Developments 42
Jan 11, 2016: NovaBay Pharmaceuticals Expects Fourth Quarter 2015 Avenova Sales to Exceed $1.5 Million 42
Appendix 43
Methodology 43
About GlobalData 43
Contact Us 43
Disclaimer 43

List of Tables
NovaBay Pharmaceuticals Inc, Medical Equipment, Key Facts, 2016 2
NovaBay Pharmaceuticals Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 2
NovaBay Pharmaceuticals Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017 5
NovaBay Pharmaceuticals Inc, Medical Equipment Deals By Type, 2011 to YTD 2017 6
NovaBay Pharmaceuticals Inc, Medical Equipment, Deals By Region, 2011 to YTD 2017 7
NovaBay Pharmaceuticals Inc, Deals By Market, 2011 to YTD 2017 8
NovaBay Pharmaceuticals Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 9
Shin Poong Enters Into Licensing Agreement With NovaBay For NeutroPhase 10
NovaBay Pharma Files Registration Statement for Public Offering of Shares 11
NovaBay Pharma Raises USD4 Million in Second and Final Tranche of Private Placement of Units 12
NovaBay Pharma Raises USD7.8 Million in First Tranche of Private Placement of Units 13
NovaBay Pharma Raises USD2.8 Million in Private Placement of Shares 14
NovaBay Pharma Raises USD6.7 Million in Public Offering of Units 15
NovaBay Pharma Completes Registered Direct Offering Of US$5.16 Million 16
Jinzi Ham to Acquire 37.14% Stake in NovaBay Pharma for USD27.06 Million 18
NovaBay Pharmaceuticals Inc, Key Competitors 19
NovaBay Pharmaceuticals Inc, Key Employees 20

★海外企業調査レポート[NovaBay Pharmaceuticals Inc (NBY)-医療機器分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Schweitzer-Mauduit International Inc (SWM):企業の財務・戦略的SWOT分析
    Schweitzer-Mauduit International Inc (SWM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengt …
  • Eolus Vind AB (EOLU B):企業の財務・戦略的SWOT分析
    Summary Eolus Vind AB (Eolus Vind) is a wind farm developer that offers construction, development, and operation of green field projects and wind power plants. The company provides services such as consultancy services, administration, financing, development, and management of wind farms. It also of …
  • UCB SA (UCB):企業の財務・戦略的SWOT分析
    UCB SA (UCB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pote …
  • Myovant Sciences Ltd (MYOV):製薬・医療:M&Aディール及び事業提携情報
    Summary Myovant Sciences Ltd (Myovant), a subsidiary of Roivant Sciences Ltd, is a biopharmaceutical company that develops and commercializes new treatments for women’s diseases and endocrine disorders. The company’s products include relugolix, an oral small molecule that functions as a gonadotropin …
  • Lonza Group Ltd (LONN):企業の財務・戦略的SWOT分析
    Lonza Group Ltd (LONN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Triphase Accelerator Corp:製薬・医療:M&Aディール及び事業提携情報
    Summary Triphase Accelerator Corp (Triphase Accelerator) is a biotechnology development company that acquires and develops novel therapeutics for the treatment of cancer. The company's pipeline products comprise marizomib, a brain-penetrant proteasome inhibitor, which is developed in both intravenou …
  • Lannett Company Inc (LCI):製薬・医療:M&Aディール及び事業提携情報
    Summary Lannett Company Inc (Lannett) is a pharmaceutical company. It develops, manufactures and distributes generic prescription pharmaceutical products in tablet, capsule and oral liquid forms. The company offers generic pharmaceuticals for medical indications such as antibiotic, cardiovascular, c …
  • Ranhill Holdings Berhad (RANHILL):企業の財務・戦略的SWOT分析
    Ranhill Holdings Berhad (RANHILL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • New York City Health and Hospitals Corp:企業の戦略的SWOT分析
    New York City Health and Hospitals Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and m …
  • Option NV (OPTI):企業の財務・戦略的SWOT分析
    Option NV (OPTI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • resTORbio Inc (TORC):製薬・医療:M&Aディール及び事業提携情報
    Summary resTORbio Inc (resTORbio) a subsidiary of Puretech Health plc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel medicines for the treatment of aging-related diseases. Its pipeline product candidate RTB101, an orally administered, small mo …
  • Dukat dd (LURA-R-A):企業の財務・戦略的SWOT分析
    Dukat dd (LURA-R-A) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Northwest Bancshares Inc:企業の戦略・SWOT・財務情報
    Northwest Bancshares Inc - Strategy, SWOT and Corporate Finance Report Summary Northwest Bancshares Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Omnicell Inc (OMCL):医療機器:M&Aディール及び事業提携情報
    Summary Omnicell Inc (Omnicell) is a provider of automation and business analytics software solutions. It provides medication control and patient safety solutions to enhance operational efficiency and patient care in acute healthcare facilities. The company offers automation solutions such as medica …
  • Bio-Rad Laboratories Inc (BIO):企業の財務・戦略的SWOT分析
    Bio-Rad Laboratories Inc (BIO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Agility Public Warehousing Co:企業の戦略・SWOT・財務情報
    Agility Public Warehousing Co - Strategy, SWOT and Corporate Finance Report Summary Agility Public Warehousing Co - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • China Gezhouba Group Co Ltd (600068):企業の財務・戦略的SWOT分析
    China Gezhouba Group Co Ltd (600068) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Grupo Televisa, S.A.B. (TLEVISACPO):企業の財務・戦略的SWOT分析
    Grupo Televisa, S.A.B. (TLEVISACPO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • McKinsey & Co Inc:企業の戦略的SWOT分析
    McKinsey & Co Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • Asiana Airlines Inc.:企業の戦略・SWOT・財務分析
    Asiana Airlines Inc. - Strategy, SWOT and Corporate Finance Report Summary Asiana Airlines Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆